29 related articles for article (PubMed ID: 16184551)
1. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo.
Monia BP; Sasmor H; Johnston JF; Freier SM; Lesnik EA; Muller M; Geiger T; Altmann KH; Moser H; Fabbro D
Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15481-4. PubMed ID: 8986837
[TBL] [Abstract][Full Text] [Related]
2. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.
Matei D; Sill MW; Lankes HA; DeGeest K; Bristow RE; Mutch D; Yamada SD; Cohn D; Calvert V; Farley J; Petricoin EF; Birrer MJ
J Clin Oncol; 2011 Jan; 29(1):69-75. PubMed ID: 21098323
[TBL] [Abstract][Full Text] [Related]
3. Integrated modulation of phorbol ester-induced Raf activation in EL4 lymphoma cells.
Han S; Meier KE
Cell Signal; 2009 May; 21(5):793-800. PubMed ID: 19263515
[TBL] [Abstract][Full Text] [Related]
4. Selective Raf inhibition in cancer therapy.
Khazak V; Astsaturov I; Serebriiskii IG; Golemis EA
Expert Opin Ther Targets; 2007 Dec; 11(12):1587-609. PubMed ID: 18020980
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotide targeting of Raf-1: importance of raf-1 mRNA expression levels and raf-1-dependent signaling in determining growth response in ovarian cancer.
Mullen P; McPhillips F; MacLeod K; Monia B; Smyth JF; Langdon SP
Clin Cancer Res; 2004 Mar; 10(6):2100-8. PubMed ID: 15041731
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).
Stevenson JP; Yao KS; Gallagher M; Friedland D; Mitchell EP; Cassella A; Monia B; Kwoh TJ; Yu R; Holmlund J; Dorr FA; O'Dwyer PJ
J Clin Oncol; 1999 Jul; 17(7):2227-36. PubMed ID: 10561280
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
Cunningham CC; Holmlund JT; Schiller JH; Geary RS; Kwoh TJ; Dorr A; Nemunaitis J
Clin Cancer Res; 2000 May; 6(5):1626-31. PubMed ID: 10815879
[TBL] [Abstract][Full Text] [Related]
8. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
Rudin CM; Holmlund J; Fleming GF; Mani S; Stadler WM; Schumm P; Monia BP; Johnston JF; Geary R; Yu RZ; Kwoh TJ; Dorr FA; Ratain MJ
Clin Cancer Res; 2001 May; 7(5):1214-20. PubMed ID: 11350886
[TBL] [Abstract][Full Text] [Related]
9. Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer.
McPhillips F; Mullen P; Monia BP; Ritchie AA; Dorr FA; Smyth JF; Langdon SP
Br J Cancer; 2001 Nov; 85(11):1753-8. PubMed ID: 11742498
[TBL] [Abstract][Full Text] [Related]
10. Comparison of strategies targeting Raf-1 mRNA in ovarian cancer.
Mullen P; McPhillips F; Monia BP; Smyth JF; Langdon SP
Int J Cancer; 2006 Mar; 118(6):1565-71. PubMed ID: 16184551
[TBL] [Abstract][Full Text] [Related]
11. First- and second-generation antisense oligonucleotide inhibitors targeted against human c-raf kinase.
Monia BP
Ciba Found Symp; 1997; 209():107-19; discussion 119-23. PubMed ID: 9383572
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
